 Christina Nelson
Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tularemia | 13 | 2025 | 30 | 7.080 |
Why?
| | Lyme Disease | 18 | 2024 | 58 | 6.510 |
Why?
| | Plague | 14 | 2023 | 60 | 6.360 |
Why?
| | Francisella tularensis | 12 | 2025 | 33 | 5.970 |
Why?
| | Yersinia pestis | 9 | 2023 | 45 | 4.760 |
Why?
| | Post-Exposure Prophylaxis | 2 | 2025 | 13 | 1.610 |
Why?
| | Bioterrorism | 6 | 2025 | 31 | 1.570 |
Why?
| | Anti-Infective Agents | 4 | 2024 | 242 | 1.530 |
Why?
| | Meningitis | 2 | 2024 | 80 | 1.450 |
Why?
| | Tick-Borne Diseases | 5 | 2021 | 11 | 1.370 |
Why?
| | Cat-Scratch Disease | 2 | 2020 | 3 | 1.150 |
Why?
| | Anti-Bacterial Agents | 11 | 2025 | 1915 | 1.130 |
Why?
| | Borrelia burgdorferi | 4 | 2021 | 21 | 1.050 |
Why?
| | Zoonoses | 4 | 2024 | 36 | 0.960 |
Why?
| | Dopamine | 2 | 2026 | 289 | 0.950 |
Why?
| | Receptors, Dopamine D2 | 1 | 2026 | 93 | 0.890 |
Why?
| | Tick Bites | 3 | 2021 | 6 | 0.840 |
Why?
| | Leukocytes | 1 | 2026 | 295 | 0.830 |
Why?
| | Aminoglycosides | 4 | 2024 | 29 | 0.800 |
Why?
| | Occupational Exposure | 3 | 2024 | 354 | 0.760 |
Why?
| | Ticks | 3 | 2018 | 29 | 0.750 |
Why?
| | Organ Transplantation | 2 | 2019 | 248 | 0.740 |
Why?
| | Strigiformes | 1 | 2022 | 3 | 0.730 |
Why?
| | Coinfection | 1 | 2023 | 141 | 0.700 |
Why?
| | Nurse Practitioners | 1 | 2023 | 140 | 0.680 |
Why?
| | Bartonella henselae | 1 | 2020 | 1 | 0.650 |
Why?
| | Chorioretinitis | 1 | 2020 | 8 | 0.650 |
Why?
| | Retinitis | 1 | 2020 | 21 | 0.640 |
Why?
| | Incidence | 11 | 2024 | 2883 | 0.640 |
Why?
| | Humans | 60 | 2026 | 144957 | 0.630 |
Why?
| | United States | 20 | 2025 | 15988 | 0.610 |
Why?
| | Ixodes | 2 | 2016 | 12 | 0.600 |
Why?
| | Hospital Costs | 1 | 2020 | 124 | 0.600 |
Why?
| | Diagnostic Errors | 2 | 2018 | 175 | 0.590 |
Why?
| | Parkinson Disease | 1 | 2026 | 600 | 0.590 |
Why?
| | Government Employees | 1 | 2018 | 2 | 0.580 |
Why?
| | Parks, Recreational | 1 | 2018 | 11 | 0.580 |
Why?
| | Pets | 1 | 2018 | 26 | 0.570 |
Why?
| | Tetracyclines | 3 | 2024 | 17 | 0.570 |
Why?
| | Vaccines | 1 | 2023 | 389 | 0.550 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2021 | 246 | 0.550 |
Why?
| | Insurance, Health | 1 | 2020 | 303 | 0.520 |
Why?
| | Female | 40 | 2026 | 78376 | 0.500 |
Why?
| | Clothing | 1 | 2016 | 23 | 0.480 |
Why?
| | Syncope | 1 | 2016 | 55 | 0.470 |
Why?
| | Bradycardia | 1 | 2016 | 59 | 0.470 |
Why?
| | Male | 33 | 2026 | 72406 | 0.460 |
Why?
| | Animals | 21 | 2026 | 38109 | 0.460 |
Why?
| | Diagnostic Test Approval | 1 | 2014 | 1 | 0.420 |
Why?
| | Infant | 12 | 2022 | 10039 | 0.420 |
Why?
| | Young Adult | 15 | 2021 | 14126 | 0.400 |
Why?
| | Seasons | 5 | 2024 | 556 | 0.400 |
Why?
| | Brain | 1 | 2026 | 2941 | 0.390 |
Why?
| | Hot Temperature | 1 | 2016 | 407 | 0.390 |
Why?
| | Dogs | 4 | 2024 | 438 | 0.380 |
Why?
| | Pituitary Neoplasms | 1 | 2015 | 190 | 0.380 |
Why?
| | Middle Aged | 20 | 2026 | 35928 | 0.380 |
Why?
| | Hodgkin Disease | 1 | 2015 | 171 | 0.370 |
Why?
| | Fluoroquinolones | 2 | 2024 | 45 | 0.360 |
Why?
| | Child | 15 | 2024 | 22657 | 0.350 |
Why?
| | Zika Virus | 3 | 2018 | 132 | 0.350 |
Why?
| | Africa | 2 | 2023 | 116 | 0.350 |
Why?
| | Adult | 22 | 2024 | 40506 | 0.350 |
Why?
| | Abortion, Spontaneous | 2 | 2024 | 115 | 0.340 |
Why?
| | Infant, Newborn | 9 | 2024 | 6434 | 0.340 |
Why?
| | Zika Virus Infection | 3 | 2018 | 168 | 0.330 |
Why?
| | Central Nervous System Diseases | 1 | 2011 | 74 | 0.330 |
Why?
| | Asphyxia Neonatorum | 1 | 2010 | 18 | 0.330 |
Why?
| | Population Surveillance | 4 | 2021 | 485 | 0.330 |
Why?
| | Immunocompromised Host | 1 | 2011 | 201 | 0.310 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 157 | 0.310 |
Why?
| | Hospitalization | 1 | 2020 | 2434 | 0.300 |
Why?
| | Clinical Competence | 1 | 2018 | 1244 | 0.300 |
Why?
| | Child, Preschool | 10 | 2020 | 11799 | 0.300 |
Why?
| | Manuscripts, Medical as Topic | 1 | 2009 | 5 | 0.300 |
Why?
| | Peer Review, Research | 1 | 2009 | 36 | 0.290 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1358 | 0.280 |
Why?
| | Premature Birth | 2 | 2024 | 380 | 0.270 |
Why?
| | Tuberculosis | 1 | 2011 | 291 | 0.270 |
Why?
| | Resuscitation | 1 | 2010 | 302 | 0.270 |
Why?
| | Aged | 15 | 2026 | 25947 | 0.270 |
Why?
| | Adolescent | 15 | 2020 | 22453 | 0.260 |
Why?
| | Dermatology | 1 | 2009 | 128 | 0.260 |
Why?
| | Guidelines as Topic | 1 | 2009 | 268 | 0.250 |
Why?
| | Sex Factors | 4 | 2017 | 2114 | 0.250 |
Why?
| | Disease Outbreaks | 3 | 2020 | 422 | 0.250 |
Why?
| | Age Factors | 5 | 2018 | 3335 | 0.250 |
Why?
| | Health Care Surveys | 2 | 2019 | 539 | 0.250 |
Why?
| | Influenza Vaccines | 1 | 2011 | 529 | 0.240 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 1182 | 0.230 |
Why?
| | Ultrasonic Therapy | 1 | 2025 | 16 | 0.230 |
Why?
| | Lipolysis | 1 | 2025 | 46 | 0.230 |
Why?
| | Influenza, Human | 1 | 2011 | 617 | 0.220 |
Why?
| | Bartonella | 2 | 2016 | 8 | 0.220 |
Why?
| | Bartonella Infections | 2 | 2016 | 5 | 0.220 |
Why?
| | Insect Repellents | 2 | 2021 | 7 | 0.210 |
Why?
| | Ibogaine | 1 | 2024 | 8 | 0.210 |
Why?
| | Trench Fever | 1 | 2024 | 5 | 0.210 |
Why?
| | Bartonella quintana | 1 | 2024 | 5 | 0.210 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2017 | 428 | 0.210 |
Why?
| | Ciprofloxacin | 1 | 2024 | 26 | 0.200 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2024 | 59 | 0.200 |
Why?
| | Endocarditis, Bacterial | 1 | 2024 | 44 | 0.200 |
Why?
| | Antibodies, Bacterial | 3 | 2019 | 148 | 0.200 |
Why?
| | Abscess | 1 | 2024 | 75 | 0.200 |
Why?
| | History, 21st Century | 3 | 2024 | 219 | 0.200 |
Why?
| | Streptococcus | 1 | 2023 | 29 | 0.190 |
Why?
| | Fever | 2 | 2022 | 312 | 0.190 |
Why?
| | Chloramphenicol | 1 | 2022 | 11 | 0.190 |
Why?
| | Public Health Surveillance | 3 | 2021 | 83 | 0.190 |
Why?
| | Wyoming | 2 | 2019 | 27 | 0.180 |
Why?
| | Autopsy | 1 | 2022 | 94 | 0.180 |
Why?
| | Aged, 80 and over | 6 | 2024 | 8279 | 0.170 |
Why?
| | Receptors, Nicotinic | 1 | 2024 | 323 | 0.170 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2642 | 0.170 |
Why?
| | Nicotine | 1 | 2024 | 332 | 0.170 |
Why?
| | Syndecan-1 | 1 | 2021 | 43 | 0.170 |
Why?
| | Smoke Inhalation Injury | 1 | 2021 | 30 | 0.170 |
Why?
| | Insecticides | 1 | 2021 | 42 | 0.170 |
Why?
| | Dancing | 1 | 2020 | 19 | 0.160 |
Why?
| | Insurance Claim Review | 1 | 2021 | 83 | 0.160 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2020 | 23 | 0.160 |
Why?
| | Asia | 1 | 2020 | 70 | 0.160 |
Why?
| | Databases, Factual | 2 | 2016 | 1486 | 0.160 |
Why?
| | Gentamicins | 1 | 2020 | 51 | 0.160 |
Why?
| | Pregnancy | 7 | 2024 | 7191 | 0.150 |
Why?
| | Virginia | 1 | 2019 | 55 | 0.150 |
Why?
| | Relapsing Fever | 1 | 2019 | 2 | 0.150 |
Why?
| | Caves | 1 | 2019 | 3 | 0.150 |
Why?
| | Maryland | 1 | 2019 | 66 | 0.150 |
Why?
| | Sentinel Surveillance | 1 | 2019 | 46 | 0.150 |
Why?
| | Dog Diseases | 1 | 2020 | 70 | 0.150 |
Why?
| | Hyaluronic Acid | 1 | 2021 | 208 | 0.150 |
Why?
| | Pseudomonas Infections | 1 | 2021 | 221 | 0.150 |
Why?
| | Bites and Stings | 1 | 2018 | 30 | 0.140 |
Why?
| | Data Collection | 1 | 2021 | 635 | 0.140 |
Why?
| | Odds Ratio | 1 | 2021 | 1077 | 0.140 |
Why?
| | Seroepidemiologic Studies | 1 | 2018 | 172 | 0.140 |
Why?
| | Vermont | 1 | 2018 | 13 | 0.140 |
Why?
| | Semen | 1 | 2018 | 23 | 0.140 |
Why?
| | Virus Shedding | 1 | 2018 | 48 | 0.140 |
Why?
| | Muscle Strength | 1 | 2020 | 330 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2018 | 3608 | 0.130 |
Why?
| | Postural Balance | 1 | 2020 | 240 | 0.130 |
Why?
| | Sciuridae | 1 | 2019 | 152 | 0.130 |
Why?
| | Blood Donors | 1 | 2019 | 143 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 475 | 0.130 |
Why?
| | Biological Warfare | 1 | 2017 | 2 | 0.130 |
Why?
| | Water | 2 | 2021 | 469 | 0.130 |
Why?
| | Manuals as Topic | 1 | 2016 | 16 | 0.130 |
Why?
| | RNA, Viral | 2 | 2018 | 688 | 0.130 |
Why?
| | Clinical Laboratory Techniques | 1 | 2017 | 96 | 0.130 |
Why?
| | Insurance Claim Reporting | 1 | 2016 | 26 | 0.120 |
Why?
| | Nymph | 1 | 2016 | 4 | 0.120 |
Why?
| | Tinea | 1 | 2016 | 2 | 0.120 |
Why?
| | Pneumonia, Bacterial | 1 | 2017 | 113 | 0.120 |
Why?
| | Lymphatic Diseases | 1 | 2016 | 20 | 0.120 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2947 | 0.120 |
Why?
| | Humidity | 1 | 2016 | 52 | 0.120 |
Why?
| | HIV Infections | 1 | 2011 | 3154 | 0.120 |
Why?
| | Doxycycline | 1 | 2016 | 62 | 0.120 |
Why?
| | Administration, Topical | 1 | 2016 | 150 | 0.120 |
Why?
| | Immunoenzyme Techniques | 1 | 2016 | 200 | 0.120 |
Why?
| | Exercise Therapy | 1 | 2020 | 473 | 0.120 |
Why?
| | Tissue Donors | 1 | 2019 | 424 | 0.120 |
Why?
| | Risk Factors | 6 | 2024 | 10792 | 0.120 |
Why?
| | Immunoblotting | 1 | 2016 | 300 | 0.120 |
Why?
| | Laboratories | 1 | 2016 | 109 | 0.110 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 38 | 0.110 |
Why?
| | Antifungal Agents | 1 | 2016 | 149 | 0.110 |
Why?
| | Office Visits | 1 | 2015 | 90 | 0.110 |
Why?
| | Neutrophils | 1 | 2021 | 1134 | 0.110 |
Why?
| | Bacterial Infections | 1 | 2017 | 246 | 0.110 |
Why?
| | Public Health | 1 | 2020 | 566 | 0.110 |
Why?
| | Symptom Assessment | 1 | 2016 | 137 | 0.110 |
Why?
| | Disease Progression | 1 | 2022 | 2852 | 0.110 |
Why?
| | Sepsis | 1 | 2021 | 641 | 0.110 |
Why?
| | Cold Temperature | 1 | 2016 | 209 | 0.110 |
Why?
| | Cross Infection | 1 | 2017 | 262 | 0.110 |
Why?
| | Culture Techniques | 1 | 2014 | 67 | 0.110 |
Why?
| | Biomarkers | 1 | 2026 | 4275 | 0.110 |
Why?
| | Physicians, Primary Care | 1 | 2016 | 207 | 0.100 |
Why?
| | Nurses | 1 | 2016 | 178 | 0.100 |
Why?
| | Cost of Illness | 1 | 2016 | 321 | 0.100 |
Why?
| | Myocarditis | 1 | 2014 | 102 | 0.100 |
Why?
| | United States Food and Drug Administration | 1 | 2014 | 205 | 0.100 |
Why?
| | Vaccination | 2 | 2012 | 1423 | 0.090 |
Why?
| | Death, Sudden, Cardiac | 1 | 2014 | 230 | 0.090 |
Why?
| | Environmental Exposure | 1 | 2017 | 590 | 0.090 |
Why?
| | Kidney Transplantation | 1 | 2019 | 704 | 0.090 |
Why?
| | Heart Transplantation | 1 | 2019 | 736 | 0.090 |
Why?
| | Nurseries, Hospital | 1 | 2012 | 5 | 0.090 |
Why?
| | Obesity | 1 | 2025 | 3082 | 0.090 |
Why?
| | Outpatients | 1 | 2015 | 443 | 0.090 |
Why?
| | Hepatitis B Vaccines | 1 | 2012 | 43 | 0.090 |
Why?
| | Hepatitis B | 1 | 2012 | 66 | 0.080 |
Why?
| | Nepal | 1 | 2010 | 32 | 0.080 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 5872 | 0.080 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 1327 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 6053 | 0.080 |
Why?
| | Intensive Care, Neonatal | 1 | 2010 | 42 | 0.080 |
Why?
| | Muscle, Skeletal | 1 | 2020 | 1796 | 0.080 |
Why?
| | Lung | 2 | 2021 | 4109 | 0.080 |
Why?
| | Bacteremia | 1 | 2012 | 221 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2020 | 17101 | 0.080 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2012 | 193 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2925 | 0.070 |
Why?
| | Health Policy | 1 | 2012 | 401 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1563 | 0.070 |
Why?
| | Colombia | 2 | 2017 | 42 | 0.060 |
Why?
| | Interviews as Topic | 1 | 2010 | 901 | 0.060 |
Why?
| | Fatal Outcome | 2 | 2017 | 307 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3415 | 0.060 |
Why?
| | Sex Distribution | 2 | 2016 | 386 | 0.050 |
Why?
| | Colorado | 2 | 2012 | 4564 | 0.050 |
Why?
| | Nicotinic Antagonists | 1 | 2024 | 37 | 0.050 |
Why?
| | Xenopus laevis | 1 | 2024 | 105 | 0.050 |
Why?
| | Self Administration | 1 | 2024 | 124 | 0.050 |
Why?
| | Oocytes | 1 | 2024 | 178 | 0.050 |
Why?
| | Interneurons | 1 | 2024 | 128 | 0.050 |
Why?
| | Nucleus Accumbens | 1 | 2024 | 135 | 0.050 |
Why?
| | Nicotinic Agonists | 1 | 2024 | 137 | 0.050 |
Why?
| | Synaptic Transmission | 1 | 2024 | 290 | 0.040 |
Why?
| | Glycocalyx | 1 | 2021 | 30 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2025 | 653 | 0.040 |
Why?
| | Capillary Permeability | 1 | 2021 | 134 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2021 | 174 | 0.040 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2020 | 42 | 0.040 |
Why?
| | Anorexia | 1 | 2020 | 17 | 0.040 |
Why?
| | Animals, Domestic | 1 | 2019 | 17 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2020 | 312 | 0.040 |
Why?
| | Random Allocation | 1 | 2020 | 363 | 0.040 |
Why?
| | New Mexico | 1 | 2020 | 99 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2024 | 2032 | 0.040 |
Why?
| | Permethrin | 1 | 2019 | 3 | 0.040 |
Why?
| | Gene Deletion | 1 | 2021 | 389 | 0.040 |
Why?
| | Motor Activity | 1 | 2024 | 722 | 0.040 |
Why?
| | Recreation | 1 | 2019 | 27 | 0.040 |
Why?
| | Farmers | 1 | 2019 | 69 | 0.040 |
Why?
| | Arvicolinae | 1 | 2019 | 32 | 0.040 |
Why?
| | Medicare | 1 | 2024 | 887 | 0.040 |
Why?
| | History, 20th Century | 1 | 2019 | 325 | 0.030 |
Why?
| | Pseudomonas aeruginosa | 1 | 2021 | 356 | 0.030 |
Why?
| | Texas | 1 | 2019 | 278 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 1253 | 0.030 |
Why?
| | Arkansas | 1 | 2017 | 21 | 0.030 |
Why?
| | Survival Analysis | 1 | 2021 | 1385 | 0.030 |
Why?
| | Arizona | 1 | 2017 | 81 | 0.030 |
Why?
| | Glanders | 1 | 2017 | 1 | 0.030 |
Why?
| | Typhus, Epidemic Louse-Borne | 1 | 2017 | 1 | 0.030 |
Why?
| | Melioidosis | 1 | 2017 | 5 | 0.030 |
Why?
| | Biological Warfare Agents | 1 | 2017 | 3 | 0.030 |
Why?
| | Anthrax | 1 | 2017 | 9 | 0.030 |
Why?
| | Smallpox | 1 | 2017 | 10 | 0.030 |
Why?
| | Botulism | 1 | 2017 | 8 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 341 | 0.030 |
Why?
| | Neurologic Examination | 1 | 2017 | 131 | 0.030 |
Why?
| | Placenta | 1 | 2024 | 780 | 0.030 |
Why?
| | Knee Joint | 1 | 2020 | 426 | 0.030 |
Why?
| | Geography, Medical | 1 | 2016 | 11 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 965 | 0.030 |
Why?
| | Serologic Tests | 1 | 2016 | 53 | 0.030 |
Why?
| | Georgia (Republic) | 1 | 2016 | 4 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2011 | 11695 | 0.030 |
Why?
| | Pregnancy Trimester, Third | 1 | 2016 | 115 | 0.030 |
Why?
| | Viral Load | 1 | 2018 | 526 | 0.030 |
Why?
| | Microcephaly | 1 | 2016 | 103 | 0.030 |
Why?
| | Mice | 2 | 2024 | 18365 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 870 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 965 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 983 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 3125 | 0.030 |
Why?
| | Age Distribution | 1 | 2014 | 403 | 0.030 |
Why?
| | Health Surveys | 1 | 2015 | 518 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 5997 | 0.020 |
Why?
| | Hepatitis B virus | 1 | 2012 | 33 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1990 | 0.020 |
Why?
| | Perinatal Care | 1 | 2012 | 62 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1813 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4569 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 675 | 0.020 |
Why?
| | Rats | 1 | 2016 | 5614 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 7183 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7997 | 0.010 |
Why?
| | Risk Assessment | 1 | 2014 | 3676 | 0.010 |
Why?
|
|
Nelson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|